Early Psychosis Translational Research
| Select | Protocol | ID |
|---|---|---|
|
#660401 |
|
|
#660201 |
|
|
#662601 |
|
|
#660601 |
|
|
#660101 |
|
|
#660701 |
|
|
#660702 |
|
|
#660801 |
|
|
#660301 |
|
|
#660501 |
Release Date:
January 17, 2017
Scope of Collection
| Element Considered | Final Measures in Toolkit |
|---|---|
| Family History of Mental Illness | Family History of Mental Illness |
| Adverse Life Events | |
| Premorbid Functioning | Premorbid Adjustment in Psychosis |
| Medical History | |
| Psychiatric Treatment History (including medication history, previous psychosocial interventions, inpatient treatment episodes, emergency department visits and antipsychotic medications at time of enrollments) | |
| Prodromal Psychosis Symptoms | |
| Age of First Prodromal Symptoms | |
| Age of First Psychotic-Level Symptoms | |
| Duration of Untreated Psychosis | |
| Positive Syndrome Symptoms | Clinician-Administered Psychiatric Assessment |
| Global Psychopathology Rating Scale | |
| Current Physical Health (including medication side effects, smoking and cardio-metabolic risk factors) | Physical Activity |
| Antipsychotic Medication Adherence | |
| Antipsychotic Medication Extrapyramidal Side Effects | |
| Multi-dimensional Assessment of Antipsychotic Medication Side Effects | |
| Social and Role Functioning | Social and Role Dysfunction in Psychosis and Schizophrenia |
| Arrests or Incarceration | Incarceration |
| Family Burden | Family Burden of Mental Illness |
| Family Expressed Emotion Toward Relatives with Psychosis and Schizophrenia | |
| Family Functioning | |
| Outpatient Treatments | Mental Health Services Satisfaction |
| Hospitalizations for Psychiatric and Medical Illness (number, duration) | |
| Emergency Department Visits, Crisis Intervention Services | |
| Well-being/Mental Health Recovery | Personal Well Being |
| Quality of Life | |
| Hiring, Training and retention of Coordinated Specialty Care (CSC) staff | |
| Availability of Required CSC Treatment Components | |
| Fidelity Measures Related to Team-based CSC Treatment Model | |
| Quality Measures Related to Provision of CSC Services | |
| Outcome Measures Related to Symptoms, Functioning and Physical Health | |
| CSC Clinic Caseload Size | |
| Measures Related to Initial Engagement (e.g., Client, Family Member, Participation) | |
| Measures Related to Participant Retention/Drop out | |
| Measures of Client and Family Member Satisfaction | Mental Health Services Satisfaction |
| Perception of Recovery Orientation and Care Quality of Mental Health Services | |
| Psychosis Recovery Assessment | |
| Shared Decision Making in Clinical Encounters | |
| Neurocognitive Assessments | Auditory Vigilance |
| Relational Encoding and Retrieval | |
| Context Processing | |
| Global Cognitive Functioning | |
| Electrophysiological Assessments (e.g., ERP) | |
| Eye-Tracking (pre- and Anti-saccade tasks) | |
| Biomarkers and Behavioral Indicators that Predict to Trajectory of Illness | C-Reactive Protein in Serum |
| Functional Brain Imaging Measures | Brain Connectivity and Activation |
| Structural Brain Imaging Measures | Brain Anatomical Imaging |
| Risk and Protective Factors that Span Modalities and Levels of Analysis (e.g., genetic, Brain, Neurobiological, Environmental and Behavioral) and Predict Movement along the illness Trajectory. (Source NIMH Strategic Plan) | |
| Family History of Mental Illness | Family History of Mental Illness |
| Adverse life Events | |
| Premorbid Functioning | Premorbid Adjustment in Psychosis |
| Medical History | |
| Psychiatric Treatment History (including medication history, previous psychosocial interventions, inpatient treatment episodes, emergency department visits and antipsychotic medications at time of enrollments) | |
| Prodromal Psychosis Symptoms | |
| Age of First Prodromal Symptoms | |
| Age of First Psychotic-Level Symptoms | |
| Duration of Untreated Psychosis | |
| Positive Syndrome Symptoms | Clinician-Administered Psychiatric Assessment |
| Global Psychopathology Rating Scale | |
| Current Physical Health (including medication side effects, smoking and cardio-metabolic risk factors) | Physical Activity |
| Antipsychotic Medication Adherence | |
| Antipsychotic Medication Extrapyramidal Side Effects | |
| Multi-dimensional Assessment of Antipsychotic Medication Side Effects | |
| Social and Role Functioning | Social and Role Dysfunction in Psychosis and Schizophrenia |
| Arrests or Incarceration | Incarceration |
| Family Burden | Family Burden of Mental Illness |
| Family Expressed Emotion Toward Relatives with Psychosis and Schizophrenia | |
| Family Functioning | |
| Outpatient Treatments | Mental Health Services Satisfaction |
| Hospitalizations for Psychiatric and Medical Illness (number, duration) | |
| Emergency Department Visits, Crisis Intervention Services | |
| Well-being/Mental Health Recovery | Personal Well Being |
| Quality of Life | |
| Hiring, Training and retention of Coordinated Specialty Care (CSC) staff | |
| Availability of Required CSC Treatment Components | |
| Fidelity Measures Related to Team-based CSC Treatment Model | |
| Quality Measures Related to Provision of CSC Services | |
| Outcome Measures Related to Symptoms, Functioning and Physical Health | |
| CSC Clinic Caseload Size | |
| Measures Related to Initial Engagement (e.g., Client, Family Member, Participation) | |
| Measures Related to Participant Retention/Drop out | |
| Measures of Client and Family Member Satisfaction | Mental Health Services Satisfaction |
| Perception of Recovery Orientation and Care Quality of Mental Health Services | |
| Psychosis Recovery Assessment | |
| Shared Decision Making in Clinical Encounters | |
| Neurocognitive Assessments | Auditory Vigilance |
| Relational Encoding and Retrieval | |
| Context Processing | |
| Global Cognitive Functioning | |
| Electrophysiological Assessments (e.g., ERP) | |
| Eye-Tracking (pre- and Anti-saccade tasks) | |
| Biomarkers and Behavioral Indicators that Predict to Trajectory of Illness | C-Reactive Protein in Serum |
| Functional Brain Imaging Measures | Brain Connectivity and Activation |
| Structural Brain Imaging Measures | Brain Anatomical Imaging |
| Risk and Protective Factors that Span Modalities and Levels of Analysis (e.g., genetic, Brain, Neurobiological, Environmental and Behavioral) and Predict Movement along the illness Trajectory. (Source NIMH Strategic Plan) |
Working Group Roster:
Clinical Services Panel:
|
Lisa Dixon, MD, MPH (Co-Chair) Columbia University Medical Center New York, NY |
Diana Perkins, MD, MPH University of North Carolina School of Medicine Chapel Hill, NC |
|
Nev Jones, PhD Felton Institute San Francisco, CA |
Rachel Loewy, PhD University of San Francisco School of Medicine San Francisco, CA |
|
Tamara Sale, MA Portland State University Portland, OR |
Translational Research Panel:
|
Dost Öngür, MD, PhD (Co-Chair) McLean Hospital Belmont, MA |
|
|
Cameron S. Carter, MD University of California, Davis Sacramento, CA |
Raquel Gur, MD, PhD University of Pennsylvania Perelman School of Medicine Philadelphia, PA |
|
Akira Sawa, MD, PhD Johns Hopkins Hospital Baltimore, MD |
Larry J. Seidman, PhD Harvard Medical School Boston, MA |
|
Carol Tamminga, MD University of Texas Southwestern Medical School Dallas, TX |
Mental Health Research Panel Liaison, WG Manager and WG Supervisor:
|
Violet Devairakkam, WG Manager RTI International Rockville, MD |
Marcie Rathbun, BS, WG Manager RTI International Research Triangle Park, NC |
|
Rebecca Boyles, MS, WG Supervisor RTI International Research Triangle Park, NC |
Wayne Huggins, PhD, WG Supervisor RTI International Research Triangle Park, NC |
National Institute of Mental Health Liaison:
|
Gregory K. Farber, PhD National Institute of Mental Health (NIMH) Office of Technology Development and Coordination (Director) Bethesda, MD |
Robert K. Heinssen, PhD National Institute of Mental Health (NIMH) Division of Services and Intervention Research (Director) Bethesda, MD |
Substance Abuse and Mental Health Services (SAMHSA) Liaison:
|
Paolo del Vecchio, MSW Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Mental Health Services (Director) Rockville, MD |
National Human Genome Research Institute (NHGRI) Liaison:
|
Margaret Ginoza National Human Genome Research Institute (NHGRI) Scientific Program Analyst Bethesda, MD |
Brenda Iglesias, BA National Human Genome Research Institute (NHGRI) Scientific Program Analyst Bethesda, MD |
|
Erin M. Ramos, PhD, MPH National Human Genome Research Institute (NHGRI) Bethesda, MD |
Supplemental Information includes protocols that the Working Group or Expert Review Panel considered useful and highly relevant to the domain but do not meet the criteria for inclusion in the Toolkit.
Early Psychosis Collection Supplemental Information includes:- SI 07 Negative Psychosis Symptoms Negative Symptom Assessment NSA
- SI 06 Clinician Administered Neuropsychiatric Interview MINI
- SI 05 Prodromal Psychosis Symptoms SIPS
- SI 04 Glutathione
- SI 03 Brain Activation and Connectivity
- SI 02 Chemical Brain Imaging
- SI 01 White Matter Integrity
Additional Information:
There is no additional information for this collection.